Dear Friend,

In these times of elections, climate chaos and COVID-19, independent news is more important than ever. You turn to Democracy Now! because you trust that when we're reporting on the pandemic or the uprisings against police brutality—or the climate crisis—our coverage is not brought to you by the fossil fuel, insurance or weapons industries or Big Pharma. We count on YOU to make our work possible. Today, a generous supporter will DOUBLE your new monthly donation to Democracy Now!, meaning your gift will go twice as far. This is a challenging time for us all, but if you're able to make a monthly donation and provide us with support we can rely on all year, please do so today. Stay safe, and thank you so much.
-Amy Goodman

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.


Gilead Accused of Neglecting Coronavirus Drug Research in Bid to Maximize Profits

HeadlineAug 06, 2020

The watchdog group Public Citizen has accused pharmaceutical giant Gilead of putting profit ahead of public health as it works to develop a treatment for the coronavirus. Public Citizen says Gilead has focused on promoting remdesivir as a possible treatment, instead of a related drug that may be more effective and easier to manufacture, because Gilead’s patent on remdesivir is five years longer.

Dr. Michael Abrams of Public Citizen said, “It is sadly predictable that Big Pharma responds to a global pandemic by trying to bring to market only those drugs that maximize its profits.” Meanwhile, Johnson & Johnson has reached a $1 billion deal with the U.S. to make 100 million doses of an experimental COVID-19 vaccine still being tested.

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation